Loading...
•
Mar 31, 2021
Organogenesis Q1 2021 Earnings Report
Reported a strong start to 2021 with significant revenue growth and improved profitability.
Key Takeaways
Organogenesis Holdings Inc. reported a strong first quarter in 2021, with net revenue increasing by 66% to $102.6 million compared to the first quarter of 2020. The company also saw a significant increase in net income, reporting $9.9 million compared to a net loss of $16.3 million in the same period last year.
Net revenue increased by 66% to $102.6 million compared to Q1 2020.
Advanced Wound Care products revenue increased by 77% compared to Q1 2020.
Surgical & Sports Medicine products revenue increased by 13% compared to Q1 2020.
Net income was $9.9 million, a significant improvement from the net loss of $16.3 million in Q1 2020.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.comSurgical & Sports Medicine Revenue
CapyFin.com Forward Guidance
For the twelve months ended December 31, 2021, the Company now expects net revenue of between $438 million and $454 million and GAAP net income and Adjusted EBITDA positive.
Positive Outlook
- Net revenue of between $438 million and $454 million, representing an increase of approximately 29% to 34% year-over-year
- Net revenue from Advanced Wound Care products of between $409 million and $422 million, representing an increase of approximately 39% to 43% year-over-year
- Net revenue from the sale of PuraPly products of between $179 million and $187 million, representing an increase of approximately 22% to 27% year-over-year
- GAAP net income positive
- Adjusted EBITDA positive
Challenges Ahead
- Net revenue from Surgical & Sports Medicine products of between $29 million and $32 million, representing a decrease of approximately 27% to 34% year-over-year
Revenue & Expenses
Visualization of income flow from segment revenue to net income